• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

VILDAGLIPTIN Drug Record

  • Summary
  • Interactions
  • Claims
  • VILDAGLIPTIN chembl:CHEMBL142703 Approved

    Alternate Names:

    NVP-LAF237
    NVP-LAF 237
    LAF 237
    LAF-237
    VILDAGLIPTIN
    GALVUS
    LAF237
    GALVUS®
    JALRA
    XILIARX
    NVP-LAF-237
    EQUA
    chemidplus:274901-16-5
    rxcui:596554
    pubchem.compound:6918537
    drugbank:04876
    chembl:CHEMBL142703

    Drug Info:

    FDA Approval approved
    Drug Class small molecule
    Drug Indications antidiabetic
    Drug Categories pyrrolidines
    Drug Categories agents causing angioedema
    Drug Categories blood glucose lowering agents
    Drug Categories nitriles
    (3 More Sources)

    Publications:

    Gupta et al., 2009, Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes., Curr Drug Targets
    Ahrén et al., 2004, Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes., Diabetes Care
    Mentlein et al., 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum., Eur. J. Biochem.
    Javorský M et al., 2016, A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins., Diabetes Obes Metab
  • VILDAGLIPTIN   DPP4

    Interaction Score: 3.92

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name vildagliptin, LAF 237,Galvus, Equa
    Novel drug target Established target
    Mechanism of Interaction Dipeptidyl peptidase IV inhibitor

    PMIDs:
    19149538 15562200 8100523


    Sources:
    DrugBank TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD

  • VILDAGLIPTIN   GLP1R

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27160388


    Sources:
    PharmGKB

  • DrugBank: DB04876

    • Version: 5.1.7

    Alternate Names:
    VILDAGLIPTIN DrugBank Drug Name
    274901-16-5 CAS Number
    EQUA Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Gupta et al., 2009, Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes., Curr Drug Targets
    Mentlein et al., 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum., Eur. J. Biochem.
    Ahrén et al., 2004, Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes., Diabetes Care

  • TdgClinicalTrial: VILDAGLIPTIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidiabetic
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • PharmGKB: vildagliptin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Javorský M et al., 2016, A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins., Diabetes Obes Metab

  • TTD: Vildagliptin

    • Version: 2020.06.01

    Alternate Names:
    D0L3DK TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 178102929

    • Version: 29-September-2020

    Alternate Names:
    VILDAGLIPTIN GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL142703

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL142703

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21